Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.55 +0.61 (+4.67%)
Streaming Delayed Price Updated: 11:18 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in September Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.